BR112022002727A2 - Peptídeos para tratamento de atrofia muscular - Google Patents

Peptídeos para tratamento de atrofia muscular

Info

Publication number
BR112022002727A2
BR112022002727A2 BR112022002727A BR112022002727A BR112022002727A2 BR 112022002727 A2 BR112022002727 A2 BR 112022002727A2 BR 112022002727 A BR112022002727 A BR 112022002727A BR 112022002727 A BR112022002727 A BR 112022002727A BR 112022002727 A2 BR112022002727 A2 BR 112022002727A2
Authority
BR
Brazil
Prior art keywords
peptides
muscle
atrophy
individuals
muscular atrophy
Prior art date
Application number
BR112022002727A
Other languages
English (en)
Inventor
Khaldi Nora
Lopez Cyril
Adelfio Alessandro
Original Assignee
Nuritas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuritas Ltd filed Critical Nuritas Ltd
Publication of BR112022002727A2 publication Critical patent/BR112022002727A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

PEPTÍDEOS PARA TRATAMENTO DE ATROFIA MUSCULAR. A presente invenção refere-se a vários peptídeos que são capazes de fosforilar a proteína ribossomal S6 (rpS6) através de uma gama de concentrações em ensaios de células in vitro de uma forma dependente da dose. RPS6 é um substrato chave para proteínas quinases e é fosforilado por fatores de crescimento e mitógenos durante o crescimento celular e divisão celular. Este é um passo fundamental na síntese de novas proteínas no tecido muscular esquelético. Os peptídeos descritos também têm a capacidade de reduzir a expressão de Transcritos de mRNA (TRIM63 e FBXO32) que estão diretamente ligados ao aumento da degradação proteica, resultando em Atrofia Muscular Esquelética progressiva. Além disso, os aumentos na atrofia muscular estão ligados ao aumento sistêmico do TNFa circulante. Os peptídeos aqui descritos também levam à expressão reduzida de TNFa em células imunes circulantes. Os peptídeos podem ser usados para promover o crescimento muscular e a saúde muscular em indivíduos que apresentam atrofia muscular, por exemplo, indivíduos idosos, pessoas fisicamente inativas e indivíduos que têm indicações caracterizadas por atrofia muscular (isto é, EM e poliomielite).
BR112022002727A 2019-08-20 2020-08-14 Peptídeos para tratamento de atrofia muscular BR112022002727A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19192689 2019-08-20
PCT/EP2020/072937 WO2021032650A1 (en) 2019-08-20 2020-08-14 Peptides for treating muscle atrophy

Publications (1)

Publication Number Publication Date
BR112022002727A2 true BR112022002727A2 (pt) 2022-08-23

Family

ID=67659544

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002727A BR112022002727A2 (pt) 2019-08-20 2020-08-14 Peptídeos para tratamento de atrofia muscular

Country Status (10)

Country Link
US (1) US20220287347A1 (pt)
EP (2) EP4017518A1 (pt)
JP (1) JP2022545265A (pt)
KR (1) KR20220103695A (pt)
CN (1) CN114650834A (pt)
AU (1) AU2020334196A1 (pt)
BR (1) BR112022002727A2 (pt)
CA (1) CA3147981A1 (pt)
MX (1) MX2022002116A (pt)
WO (1) WO2021032650A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023096233A1 (ko) * 2021-11-25 2023-06-01 (주)네오크레마 신규 펩티드 및 이의 용도
WO2023096232A1 (ko) * 2021-11-25 2023-06-01 (주)네오크레마 신규 펩티드 및 이의 용도
KR20230170490A (ko) * 2022-06-10 2023-12-19 (주)케어젠 근육 손실 저해 및 근육량 증진 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
EP1033405A3 (en) * 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
US20110214206A1 (en) * 1999-05-06 2011-09-01 La Rosa Thomas J Nucleic acid molecules and other molecules associated with plants
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
CA2434802C (en) 2001-01-16 2013-05-28 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
WO2005023290A2 (en) 2003-05-23 2005-03-17 Pestka Biomedical Laboratories, Inc. Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
JP2008526986A (ja) * 2005-01-13 2008-07-24 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 神経変性疾患、筋変性疾患または神経筋変性疾患による組織の変敗、傷害または損傷の治療方法または予防の方法あるいは前記疾患によって悪影響を受ける組織の修復方法
US8105572B2 (en) 2007-05-18 2012-01-31 New York University Method of treating tuberculosis with interferons
PL2150617T3 (pl) 2007-06-04 2015-04-30 Regeneron Pharma Wzmocniona ekspresja i regiony stabilności
EP2050437A1 (en) 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
ES2397890B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas.
KR20170002846A (ko) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 콩잎 추출물을 유효성분으로 함유하는 근질환 억제 및 예방용 조성물
EP3117831A1 (en) * 2015-07-16 2017-01-18 Nuritas Limited Peptides for use in promoting transport of glucose into skeletal muscle
EP3118216A1 (en) * 2015-07-16 2017-01-18 Nuritas Limited Cellular growth and proliferation promoting peptides, and uses thereof
EP3118215A1 (en) * 2015-07-16 2017-01-18 Nuritas Limited Anti-inflammatory peptides, and uses thereof
CA3083526A1 (en) * 2017-12-06 2019-06-13 Andrew John Geall Compositions and methods of treating muscle atrophy and myotonic dystrophy

Also Published As

Publication number Publication date
MX2022002116A (es) 2022-03-17
CA3147981A1 (en) 2021-02-25
KR20220103695A (ko) 2022-07-22
US20220287347A1 (en) 2022-09-15
AU2020334196A1 (en) 2022-03-03
EP4218787A2 (en) 2023-08-02
JP2022545265A (ja) 2022-10-26
WO2021032650A1 (en) 2021-02-25
EP4017518A1 (en) 2022-06-29
EP4218787A3 (en) 2023-12-20
CN114650834A (zh) 2022-06-21

Similar Documents

Publication Publication Date Title
BR112022002727A2 (pt) Peptídeos para tratamento de atrofia muscular
Rinnerthaler et al. Skin aging, gene expression and calcium
Salama et al. Enhanced supply of methionine or arginine alters mechanistic target of rapamycin signaling proteins, messenger RNA, and microRNA abundance in heat-stressed bovine mammary epithelial cells in vitro
Patwardhan et al. Sphingolipids and expression regulation of genes in cancer
Kashima et al. Identification of a novel hypocholesterolemic protein, major royal jelly protein 1, derived from royal jelly
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
Lin et al. Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase IIα
Dzik et al. Vitamin D deficiency is associated with muscle atrophy and reduced mitochondrial function in patients with chronic low back pain
Mirza et al. Comparison of the anticatabolic effects of leucine and Ca-β-hydroxy-β-methylbutyrate in experimental models of cancer cachexia
ES2189784T3 (es) Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
CO2021009882A2 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
Terruzzi et al. L‐Carnitine Reduces Oxidative Stress and Promotes Cells Differentiation and Bone Matrix Proteins Expression in Human Osteoblast‐Like Cells
BR112022011854A2 (pt) Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção
CO2022017445A2 (es) Proteínas multiespecíficas
BR112022001341A2 (pt) Inibidores de enzima
Neary et al. Calcium-activated, phospholipid-dependent protein kinase and protein substrates in primary cultures of astrocytes
Miyata et al. Mitogen‐activated protein kinase/extracellular signal‐regulated protein kinase activation of cultured human dental pulp cells by low‐power gallium‐aluminium‐arsenic laser irradiation
Chanmanee et al. The effects of agomelatine on endoplasmic reticulum stress related to mitochondrial dysfunction in hippocampus of aging rat model
Ren et al. Arginine inhibits the malignant transformation induced by interferon-gamma through the NF-κB-GCN2/eIF2α signaling pathway in mammary epithelial cells in vitro and in vivo
Hussien et al. Alleviation of cardiac mitochondrial dysfunction and oxidative stress underlies the protective effect of vitamin D in chronic stress-induced cardiac dysfunction in rats
Kang et al. Long-term administration of dehydroepiandrosterone accelerates glucose catabolism via activation of PI3K/Akt-PFK-2 signaling pathway in rats fed a high-fat diet
Arous et al. Oleate-mediated activation of phospholipase D and mammalian target of rapamycin (mTOR) regulates proliferation and rapamycin sensitivity of hepatocarcinoma cells
Chang et al. Triptolide inhibits tumor promoter-induced uPAR expression via blocking NF-κB signaling in human gastric AGS cells
NO20064753L (no) Kombinasjonsterapi
Maurin et al. GCN2 upregulates autophagy in response to short-term deprivation of a single essential amino acid